EGFR and non-small cell lung carcinoma: The prognosis of patients with advanced non-small cell lung cancer (NSCLC) is poor, with a 1-year survival rate after chemotherapy of only 29%.[1] Epidermal growth factor receptor (EGFR) mutations are important cancer-driving factors.